How much did Illumina's sequencing cost per human genome decline from 2010 to 2021?
Answered at 18:58 in Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing
How much did Illumina's sequencing cost per human genome decline from 2010 to 2021?
Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021. Despite this massive cost reduction, Illumina's revenue actually increased from $1 billion to $4.5 billion because applications and volumes of gene sequencing exploded higher, enabled by the greater affordability.
Full answer and detailsRead the whole answer, key facts and every other question from this episode
In short
Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021.
Guest · Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing · answer at 18:58
Key takeaways
- Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021.
Quote to remember
“Either the largest companies in the world will gobble up a larger share of profits than has ever occurred in the U.S., or the average stock will perform much better than the S&P 500 in the years ahead, as the excessive outperformance of these mega cap stocks reverts, as it has in every past instance.”
The full answer · about 3 min
Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021. Despite this massive cost reduction, Illumina's revenue actually increased from $1 billion to $4.5 billion because applications and volumes of gene sequencing exploded higher, enabled by the greater affordability.
Key facts
- S&P 500 returned 15.3% in first half of 2024; Ensemble Capital strategy returned 8%
- Average stock in S&P 500 up only 5% in first half of 2024
- Magnificent Seven stocks up 94.9% over five-quarter period versus 16.2% for average stock
- NVIDIA up 345% over past five quarters; up 2,926% over past five years versus S&P 500 up 101%
- Five largest companies in S&P 500 make up 25% of entire index—most intense concentration in at least half a century
People, companies and topics mentioned
More answers from this episode
- 1:01Why did the S&P 500 return 15.3% in the first half of 2024 while the average stock in the index returned only 5%?
- 4:16How does NVIDIA's 345% five-quarter return compare to other Magnificent Seven stocks?
- 8:16What valuation multiples do mega-cap stocks trade at compared to the S&P 500 average?
- 9:01What percentage of S&P 500 stocks have outperformed the broader index in 2024?
- 21:14What is the market size potential for Grail's multi-cancer early detection screening test?